Antimicrobial Resistance among Clinical Isolates of Pseudomonas aeruginosa from Non-tertiary Care Hospitals in Korea, 2002-2004

Jeom-Kyu LEE; Eui-Suk SOHN; Yong-Sun YOO; Jae-Il YOO; Eun-Hee LEE; Kyung-Ryul LEE; Yeong-Seon LEE; Bong-Su KIM; Jeom-Kyu LEE; Eui-Suk SOHN; Yong-Sun YOO; Jae-Il YOO; Eun-Hee LEE; Kyung-Ryul LEE; Yeong-Seon LEE; Bong-Su KIM.
Infection and Chemotherapy ; : 1-10, 2006.
Artículo en Ko | WPRIM | ID: wpr-722144

Documentos relacionados

  1. Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran.
  2. Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019.
  3. In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015-2021.
  4. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.
  5. Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units.
  6. Genotypic Detection of <i>qnrA</i> and <i>qnrC</i> Genes in <i>Citrobacter koseri</i> Isolated from Patients with Urinary Tract Infection.
  7. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
  8. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.
  9. <i>In Vitro</i> Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan.
  10. Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates.